Skip to main content

20 Result(s)

within J T Sandlund Remove this filter Oncology Remove this filter

and

  1. Article

    Treatment of recurrent sarcomas and pediatric solid tumors with ifosfamide (IF)

    I. T. Magrath, J. T. Sandlund, A. Raynor… in Journal of Cancer Research and Clinical On… (1986)

    Download PDF (139 KB)

  2. No Access

    Chapter and Conference Paper

    Use of Investigational Drugs as Initial Therapy for Childhood Solid Tumors

    Solid tumors are relatively rare in children, but comprise about two-thirds of all malignancies that affect this age group. Most of these tumors respond well to initial treatment, and some (Wilms’ tumor, low-s...

    W. H. Meyer, P. J. Houghton, M. E. Horowitz… in Modern Trends in Human Leukemia VIII (1989)

  3. No Access

    Chapter and Conference Paper

    Current Treatment and Results of St. Jude Studies for Childhood Acute Lymphoblastic Leukemia

    The Goldie-Coldman hypothesis predicts that early use of all active agents in maximum doses will increase leukemic cell kill and prevent the early emergence of drug resistance [1]. Results of contemporary clin...

    C.-H. Pui, G. K. Rivera, W. E. Evans, J. T. Sandlund, M. L. Hancock… in Acute Leukemias IV (1994)

  4. No Access

    Chapter and Conference Paper

    Risk-Adapted Treatment for Acute Lymphoblastic Leukemia: Findings from St. Jude Children’s Research Hospital

    Data from St. Jude Total Therapy Study XI were analyzed to identify clinical and biologic features with prognostic significance. Results of this analysis, along with information available in the literature, le...

    C.-H. Puil, G. K. Rivera, M. L. Hancock, J. T. Sandlund… in Acute Leukemias VI (1997)

  5. No Access

    Chapter and Conference Paper

    Pharmacodynamics in Childhood Acute Lymphoblastic Leukemia

    Pharmacokinetic variability clearly influences the outcome of treatment for acute lymphoblastic leukemia (ALL), but its utility as a clinical risk factor is limited when patients receive complex multiagent reg...

    Ching-Hon Pui, M. V. Relling, J. T. Sandlund, D. Campana… in Acute Leukemias VIII (2001)

  6. No Access

    Article

    Urolithiasis in pediatric patients with acute lymphoblastic leukemia

    We evaluated the incidence, timing, and consequences of urolithiasis in children with acute lymphoblastic leukemia (ALL). A total of 20 patients with urolithiasis were identified from 2095 patients with ALL tr...

    S C Howard, S D Kaplan, B I Razzouk, G K Rivera, J T Sandlund, R C Ribeiro… in Leukemia (2003)

  7. No Access

    Article

    Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia after first relapse

    Using flow cytometric techniques capable of detecting 0.01% leukemic cells, we prospectively studied minimal residual disease (MRD) in patients with acute lymphoblastic leukemia (ALL) after first relapse. At t...

    E Coustan-Smith, A Gajjar, N Hijiya, B I Razzouk, R C Ribeiro, G K Rivera… in Leukemia (2004)

  8. No Access

    Article

    Asparaginase pharmacodynamics differ by formulation among children with newly diagnosed acute lymphoblastic leukemia

    Polyethylene glycol-conjugated (PEG) asparaginase is approved for use in patients who develop allergy to other forms of asparaginase, although its ability to deplete asparagine systemically in patients with hy...

    L J Hak, M V Relling, C Cheng, D Pei, B Wang, J T Sandlund, J Rubnitz, C-H Pui in Leukemia (2004)

  9. No Access

    Article

    Low-dose oral etoposide-based induction regimen for children with acute lymphoblastic leukemia in first bone marrow relapse

    We evaluated the clinical response to low-dose etoposide in relapsed acute lymphoblastic leukemia (ALL). Of the 45 patients with ALL in first bone marrow relapse enrolled on the ALL R15 protocol, 44 had receiv...

    N Hijiya, A Gajjar, Z Zhang, J T Sandlund, R C Ribeiro, J E Rubnitz, S Jeha… in Leukemia (2004)

  10. No Access

    Article

    Overt testicular disease at diagnosis of childhood acute lymphoblastic leukemia: lack of therapeutic role of local irradiation

    To assess the prognosis of overt testicular disease at diagnosis of acute lymphoblastic leukemia, and any therapeutic role of irradiation for this involvement, we reviewed the data of 811 boys treated on St Ju...

    N Hijiya, W Liu, J T Sandlund, S Jeha, B I Razzouk, R C Ribeiro, J E Rubnitz… in Leukemia (2005)

  11. No Access

    Article

    Clinical consequences of hyperglycemia during remission induction therapy for pediatric acute lymphoblastic leukemia

    Hyperglycemia adversely affects outcome in adult patients with acute lymphoblastic leukemia (ALL), but its impact on children with this disease is unknown. We evaluated the relationship between hyperglycemia d...

    J R Roberson, H L Spraker, J Shelso, Y Zhou, H Inaba, M L Metzger, J E Rubnitz… in Leukemia (2009)

  12. No Access

    Article

    Effective treatment of advanced-stage childhood lymphoblastic lymphoma without prophylactic cranial irradiation: results of St Jude NHL13 study

    There has been a steady improvement in cure rates for children with advanced-stage lymphoblastic non-Hodgkin's lymphoma. To further improve cure rates whereas minimizing long-term toxicity, we designed a proto...

    J T Sandlund, C-H Pui, Y Zhou, F G Behm, M Onciu, B I Razzouk, N Hijiya… in Leukemia (2009)

  13. No Access

    Article

    Increased risk for CNS relapse in pre-B cell leukemia with the t(1;19)/TCF3-PBX1

    To evaluate the impact of contemporary therapy on the clinical outcome of children with pre-B acute lymphoblastic leukemia (ALL) and the t(1;19)/TCF3/PBX1, we analyzed 735 patients with B-cell precursor ALL treat...

    S Jeha, D Pei, S C Raimondi, M Onciu, D Campana, C Cheng, J T Sandlund… in Leukemia (2009)

  14. No Access

    Article

    Long-term results of St Jude Total Therapy Studies 11, 12, 13A, 13B, and 14 for childhood acute lymphoblastic leukemia

    We analyzed the long-term outcome of 1011 patients treated in five successive clinical trials (Total Therapy Studies 11, 12, 13A, 13B, and 14) between 1984 and 1999. The event-free survival improved significan...

    C H Pui, D Pei, J T Sandlund, R C Ribeiro, J E Rubnitz, S C Raimondi, M Onciu… in Leukemia (2010)

  15. No Access

    Article

    ETV6-RUNX1-positive childhood acute lymphoblastic leukemia: improved outcome with contemporary therapy

    ETV6-RUNX1 fusion is the most common genetic aberration in childhood acute lymphoblastic leukemia (ALL). To evaluate whether outcomes for this drug-sensitive leukemia are improved by contemporary risk-directed th...

    D Bhojwani, D Pei, J T Sandlund, S Jeha, R C Ribeiro, J E Rubnitz, S C Raimondi… in Leukemia (2012)

  16. No Access

    Article

    Clinical utility and implications of asparaginase antibodies in acute lymphoblastic leukemia

    Hypersensitivity to asparaginase is common, but the differential diagnosis can be challenging and the diagnostic utility of antibody tests is unclear. We studied allergic reactions and serum antibodies to E. coli

    C Liu, J D Kawedia, C Cheng, D Pei, C A Fernandez, X Cai, K R Crews, S C Kaste… in Leukemia (2012)

  17. No Access

    Article

    Successful challenges using native E. coli asparaginase after hypersensitivity reactions to PEGylated E. coli asparaginase

    Asparaginase is an essential component of pediatric acute lymphoblastic leukemia (ALL) therapy. However, asparaginase-induced hypersensitivity reactions can compromise its efficacy either by directly influenci...

    C. A. Fernandez, E. Stewart, J. C. Panetta… in Cancer Chemotherapy and Pharmacology (2014)

  18. No Access

    Article

    A revised definition for cure of childhood acute lymphoblastic leukemia

    With improved contemporary therapy, we reassess long-term outcome in patients completing treatment for childhood acute lymphoblastic leukemia (ALL) to determine when cure can be declared with a high degree of ...

    C H Pui, D Pei, D Campana, C Cheng, J T Sandlund, W P Bowman, M M Hudson… in Leukemia (2014)

  19. No Access

    Article

    Clinical impact of minimal residual disease in children with different subtypes of acute lymphoblastic leukemia treated with Response-Adapted therapy

    To determine the clinical significance of minimal residual disease (MRD) in patients with prognostically relevant subtypes of childhood acute lymphoblastic leukemia (ALL), we analyzed data from 488 patients tr...

    C-H Pui, D Pei, S C Raimondi, E Coustan-Smith, S Jeha, C Cheng, W P Bowman… in Leukemia (2017)

  20. No Access

    Article

    Novel ALK fusion in anaplastic large cell lymphoma involving EEF1G, a subunit of the eukaryotic elongation factor-1 complex

    G Palacios, T I Shaw, Y Li, R K Singh, M Valentine, J T Sandlund, M S Lim… in Leukemia (2017)